AP 305 - Alphageneron Pharmaceuticals
Alternative Names: AP-305 - Alphageneron PharmaceuticalsLatest Information Update: 08 Dec 2023
At a glance
- Originator Alphageneron Pharmaceuticals
- Class Antineoplastics; Drug conjugates; Immunoconjugates
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Haematological malignancies; Solid tumours
Most Recent Events
- 27 Sep 2023 Alphageneron Pharmaceuticals has multiple granted for AP 305 in the multiple countries worldwide (Alphageneron Pharmaceuticals Pipeline, September 2023)
- 27 Sep 2023 Alphageneron Pharmaceuticals has multiple pending patents for AP 305 in the multiple countries worldwide (Alphageneron Pharmaceuticals Pipeline, September 2023)
- 27 Sep 2023 Preclinical trials in Haematological malignancies in USA (Parenteral) before September 2023 (Alphageneron Pharmaceuticals Pipeline, September 2023)